Hematology and Medical Oncology: Clinical Research

[Return to search results]

Clinical Trial Details

Protocol : AZA-MDS-006 Connect MDS and AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Study Purpose
This study is observational. An observational disease registry study means that only information about your disease and medical treatment that your study doctor is already prescribing as part of your standard medical care is collected. Standard medical care is the treatment normally given for a certain condition or illness.
Study Plan
This study will observe and collect data for people with one of the three following diseases: - Myelodysplastic Syndrome (MDS) MDS is a disease where a person with the disease has low blood cell counts and bone marrow failure. Bone marrow failure is when your bone marrow is not making enough properly developed white blood cells, red blood cells or platelets. -Idiopathic Cytopenia of Undetermined Significance (ICUS) ICUS is a condition where a person has unexplained, persistent (for equal to or more than 6 months) changes in number of certain cells in the blood (red blood cells, white blood cells, platelets and granulocytes). If you have ICUS a diagnosis of Myelodysplastic Syndrome (MDS) cannot be made for certain. Persons with ICUS are at increased risk of developing MDS and AML (see above and below). -Acute Myeloid Leukemia (AML) AML is a type of cancer in which the bone marrow makes abnormal myeloblasts (a type of white blood cell), red blood cells, or platelets.

Sub Investigator
Dat C. Pham, M.D.

Sub Investigator
Lara Zuberi, M.B.B.S. (M.D.)